Plerixafor 8HCl (AMD3100 8HCl)

그림문자(GHS)

• 그림문자(GHS)

  

• 신호 어

  Danger

• 유해·위험 문구

  H226：인화성 액체 및 증기

  H314：피부에 심한 화상과 눈에 손상을 일으킴

• 예방조치문구

  P210：열·스파크·화염·고열로부터 멀리하시오 - 금연 하시오.

  P233：용기를 단단히 밀폐하시오. 용기는 환기가 잘 되는 곳에 단단히 밀폐하여 보관하시오.

  P240：용기와 수용설비를 접지 및 접합시키시오.

  P241：폭발 방지용 장비[전기적/환기/조명/...]을(를) 사용하시오.

  P242：스파크가 발생하지 않는 도구를 사용하시오

  P243：정전기 방지 조치를 취하시오.

  P264：취급 후에는 손을 철저히 씻으시오.

  P264：취급 후에는 손을 철저히 씻으시오.

  P280：보호장갑/보호의/보안경/안면보호구를 착용하시오.

  P301+P330+P331：삼켰다면 입을 씻어내시오. 토하게 하려 하지 마시오.

  P303+P361+P353：피부(또는 머리카락)에 묻으면 오염된 모든 의복은 벗거나 제거하시오 피부를 물로 씻으시오/샤워하시오.

  P363：다시 사용전 오염된 의류는 세척하시오.

  P370+P378：화재 시 불을 끄기 위해 (Section 5. 폭발, 화재시 대처방법의 적절한 소화제)을(를) 사용하시오.

  P403+P235：환기가 잘 되는 곳에 보관하고 저온으로 유지하시오.

  P405：밀봉하여 저장하시오.

Plerixafor 8HCl (AMD3100 8HCl) 화학적 특성, 용도, 생산

• 용도

  Plerixafor 8HCl (AMD3100 8HCl) is the hydrochloride of Plerixafor, a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively - See more at: http://www.selleckchem.com/products/plerixafor-8hcl-db06

• 일반 설명

  A symmetrical bicyclam compound that antagonizes CXCL12 (SDF1) binding to CXCR4 (IC₅₀ = 108 and 245 nM using rat and human CXCR4, respectively) and inhibits SDF1-induced Ca²⁺ flux (by 100% at 100 ng/ml in SUP-T1 and THP-1 cultures) as well as CXCR4-, but not CCR5-, mediated HIV infection (IC₅₀ ≤200 nM), while enhancing the binding of SDF1 to CXCR7 (by ~60% at 1 mM with CXCR7-expressing HEK293T cells) and SDF1-induced β-arrestin recruitment to CXCR7 (EC₅₀ = 6.48 and 11.8 nM, in the presence and absence of 10 μM AMD3100, respectively). Administration AMD3100 via intravenous infusion is also reported to result in hematopoietic stem cell mobilization in humans, dogs, and mice in vivo. Exhibits no inhibitory effects against chemokine-induced signaling via CXCR1/2/3 or CCR1/2/3/4/5/6/7/8/9.

• 생물학적 활성

  Highly selective CXCR4 chemokine receptor antagonist (IC 50 values are 0.02 - 0.13 and > 25 μ M for CXCR4 and all other chemokine receptors respectively). Switches inflammatory responses from Th2 to Th1 type and reduces airway hyperresponsiveness in a mouse model of asthma. Potently inhibits HIV-1 and HIV-2 replication in vitro (EC 50 = 4 - 35 nM) and mobilizes hematopoietic stem cells in vivo .

• Clinical Use

  Plerixafor hydrochloride, a chemokine CXCR4 (SDF-1) antagonist, was launched by Genzyme for the treatment of enhancing mobilization of hematopoietic stem cells for autologous transplantation in patients with lymphoma and enhancing mobilization of hematopoietic stem cells for transplantation in patients with multiple myeloma. Being a CXCR4 antagonist, a specific cellular chemokine receptor, plerixafor triggers the rapid movement of stem cells out of the bone marrow and into circulating blood where the stem cells can be collected for use in stem cell transplants. Regarding its use for cardiac applications, some clinical data suggests that the presence of stem cells circulating in the bloodstream or directly injected into the hearts of patients who have suffered a heart attack may result in improved cardiac function.

Plerixafor 8HCl (AMD3100 8HCl) 공급 업체

Global(189)Suppliers

Plerixafor 8HCl (AMD3100 8HCl) 관련 검색